Loading
A randomised phase 2 found that adding the GSK-3 inhibitor elraglusib to standard chemotherapy lengthened survival in metastatic pancreatic cancer; a phase 3 is needed to confirm it.
Part 3B of the Actuate 1801 study randomised patients with previously untreated metastatic pancreatic ductal adenocarcinoma to gemcitabine and nab-paclitaxel with or without elraglusib. The company reported improved overall survival and one-year survival with elraglusib. As a phase 2 result it is hypothesis-generating, and Actuate has said a confirmatory phase 3 is planned. The same registration, NCT03678883 (Actuate 1801), also covers the earlier dose-finding and expansion parts, in which elraglusib was given alone or with gemcitabine, doxorubicin, lomustine, carboplatin or paclitaxel to patients with refractory solid tumours or blood cancers.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Elraglusib + gemcitabine-nab-paclitaxel | 155 | 10.1 months | 0.62 (0.46 to 0.84) | 0.01 | link |
| Gemcitabine-nab-paclitaxel | 78 | 7.2 months | ||||
| Overall survival at 1 yearprimary | Elraglusib + gemcitabine-nab-paclitaxel | - | 44.1% | - | - | link |
| Gemcitabine-nab-paclitaxel | - | 22.3% | ||||
| Overall survival (modified intention to treat)primary | Elraglusib + gemcitabine/nab-paclitaxel | 155 | 10.1 months | 0.62 (0.46 to 0.84) | 0.01 | link |
| Gemcitabine/nab-paclitaxel | 78 | 7.2 months | ||||
| Overall survival at 1 yearprimary | Elraglusib + gemcitabine/nab-paclitaxel | 155 | 44.1% | - | - | link |
| Gemcitabine/nab-paclitaxel | 78 | 22.3% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine + nab-paclitaxel, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pegylated liposomal doxorubicin, Doxorubicin, Gemcitabine, Carboplatin.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Small-molecule kinase inhibitors, Pancreatic ductal adenocarcinoma.
Shares Pegylated liposomal doxorubicin, Doxorubicin, Gemcitabine.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Doxorubicin, Paclitaxel / nab-paclitaxel.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Doxorubicin, Paclitaxel / nab-paclitaxel.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Doxorubicin, Paclitaxel / nab-paclitaxel.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/